Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease

Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease

Background and Aims: Anti-tumor necrosis factor mAb (i.e., adalimumab, ADA) is currently used in the treatment of patients with Crohn’s disease (CD). However, its regulation on fecal microbiota is still not fully understood.Methods: A retrospective analysis was conducted on 115 patients with CD who...

Full description

Bibliographic Details
Main Authors: Liang Chen, Zhanjun Lu, Dengfeng Kang, Zhongsheng Feng, Gengfeng Li, Mingming Sun, Zhanju Liu, Wei Wu, Leilei Fang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
adalimumab
mucosal healing
fecal microbiota
biomarker
Crohn’s disease
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.913720/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.913720/full

Similar Items